Paratek Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of therapeutics based upon tetracycline chemistry. Its lead product candidates include Omadacycline and Sarecycline, both of which are undergoing clinical trials. It has collaborative research and license agreement with Allergan plc to research and develop tetracycline products. Paratek was incorporated in 2001 and is based in Boston, Massachusetts.